First Know Thyself: A Self-Assessment Program on Management of Atopic Dermatitis​

Allergy/ Immunology
Curriculum:
A Learning Pathway in Atopic Dermatitis: Achieving Success in Assessment and Management to Improve Patient Outcomes
Credits:
1.25 AMA PRA Category 1 Credit(s)™
Launch Date:
December 08, 2016
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Physicians, nurse practitioners, and physician assistants who specialize in allergy/immunology and dermatology

Relevant Terms:

Bradley E. Chipps, MD

Bradley E. Chipps, MD
Medical Director, Respiratory Therapy and the Cystic Fibrosis Center
Sutter Medical Center
Capital Allergy and Respiratory Disease Center
Sacramento, CA

Bradley E. Chipps, MD, received his medical degree from the University of Texas Medical Branch, Galveston, Texas. He was a pediatric resident for 2 years before serving in the Air Force at Ellsworth Air Force Base in South Dakota for 2 years as a general pediatrician. He then completed a combined allergy and pulmonary fellowship at Johns Hopkins University, Baltimore, Maryland, and spent 1 year on the faculty in the Pediatric Respiratory Sciences Division.

Dr Chipps has been in private practice in Sacramento, California, since 1979. He is the medical director of Respiratory Therapy and the Cystic Fibrosis Center at Sutter Medical Center in Sacramento and is also the associate medical director of the Sutter Community Hospitals Sleep Laboratory, which he established in 1984. He is board certified in pediatric pulmonology and allergy and clinical immunology. Dr Chipps is also president-elect of the American College of Allergy, Asthma and Immunology (ACAAI).

Lawrence F. Eichenfield, MD
 

Lawrence F. Eichenfield, MD
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
Chief, Pediatric and Adolescent Dermatology
University of California, San Diego School of Medicine
San Diego, CA

1. Describe the pathogenesis of atopic dermatitis (AD) and the "atopic march" and discuss how the underlying pathology of the disease can be used to direct therapy
2. Utilize current therapies and describe how to utilize emerging treatments for AD based on safety and efficacy data, pathophysiology, guidelines, individual patient needs, and sustained efficacy, especially in patients with moderate-to-severe AD
3. Manage quality-of-life issues, psychosocial comorbidities, and treatment-related anxiety in patients with AD
4. Engage the patient as a partner in his or her care plan to ensure best treatment adherence and outcomes

PHYSICIAN CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Bradley E. Chipps, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Genentech, Meda, Merck, and Novartis (Consulting Fees; Fees for Non-CME/CE Services).
Lawrence F. Eichenfield, MD, has affiliations with Anacor/Pfizer, Genentech, Lilly, Otsuka/Medimetriks, Regeneron/Sanofi, TopMD, and Valeant (Consulting Fees); and Kimberly Clark and Regeneron/Sanofi (Investigator).
RMEI Medical Education, LLC
Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
Chelsey Goins, PhD, has no affiliations with commercial interests to disclose.
Amy Reeve has no affiliations with commercial interests to disclose
Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Estimated time to complete: 1.25 hours
Medium: Internet
FEE INFORMATION
There is no fee for this educational activity.
COMMERCIAL SUPPORT
This activity is supported by an independent medical educational grant from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.25 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
Read the learning objectives and faculty disclosures.
Participate in the activity.
Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above